VIENNA, VIRGINIA, UNITED STATES, January 27, 2020 /EINPresswire.com/ -- There are 250,000 people with end-stage heart failure who could qualify for a heart transplant, but only 2,500-3,000 transplants are performed each year.
There have been few innovations that could actively expand the donor pool, but a new drug could change the scope of heart transplantation for years to come.
Dr. Salwa A. Elgebaly, PhD is the Founder and CEO of Nour Heart, Inc., dedicated to the development of the new cardioprotective drug, Cyclocreatine Phosphate for patients with Ischemic Heart Diseases.
“I wanted to bring this to life for the people whose stories touched me,” says Dr. Elgebaly. “I believe in Cyclocreatine phosphate.”
Prof. Salwa A. Elgebaly Celebrated for Dedication to the Field of Cardiovascular Medicine.
Prof. Elgebaly founded Nour Heart, Inc. in 2006 to pursue research into heart-related diagnostic and therapeutic products and is a Professor at the University of Connecticut Faculty of Medicine (Adj.), Farmington, Connecticut, U.S.